Entrada Therapeutics Inc (TRDA)
12.45
+0.09
(+0.73%)
USD |
NASDAQ |
Apr 26, 16:00
12.68
+0.22
(+1.81%)
After-Hours: 20:00
Entrada Therapeutics Total Liabilities (Quarterly): 226.83M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 226.83M |
| September 30, 2023 | 238.37M |
| June 30, 2023 | 287.08M |
| March 31, 2023 | 245.96M |
| December 31, 2022 | 39.50M |
| September 30, 2022 | 41.24M |
| Date | Value |
|---|---|
| June 30, 2022 | 39.88M |
| March 31, 2022 | 39.31M |
| December 31, 2021 | 7.115M |
| September 30, 2021 | 204.99M |
| June 30, 2021 | 202.53M |
| December 31, 2020 | 85.02M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
7.115M
Minimum
Dec 2021
287.08M
Maximum
Jun 2023
138.15M
Average
143.77M
Median
Total Liabilities (Quarterly) Benchmarks
| GlycoMimetics Inc | 6.902M |
| Lyell Immunopharma Inc | 95.08M |
| Candel Therapeutics Inc | 28.46M |
| Eliem Therapeutics Inc | 2.87M |
| NovaBay Pharmaceuticals Inc | 5.72M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 469.19M |
| Shareholders Equity (Quarterly) | 242.36M |
| Current Ratio | 2.329 |